Delivra Health Stock Price, News & Analysis

Delivra Health Brands (DHBUF) reported its Q3 2025 financial results, showing positive growth and strategic expansion. The company achieved a 3% year-over-year revenue increase to $9,012,000 for the nine months ended March 31, 2025, with positive adjusted EBITDA of $124,000 in Q3. Dream Water brand expanded in Canada with new product launches including Sleep Shot extensions and Sleep Gummies. LivRelief's "Quiets Chronic Pain" campaign drove a 21% increase in units sold to 95,000 units. However, gross profit margin declined to 49% from 52% due to higher costs and product mix changes. The company's strategic marketing investments led to a 15% increase in expenses to $4,585,000, impacting the nine-month adjusted EBITDA which decreased to $(51,000) from $845,000 in the previous year.

Delivra Health Brands Inc. (DHBUF) has announced the expansion of its Dream Water® brand into Middle Eastern markets through the launch of its new 60-Count Sleep Gummies. The product will be distributed through the company's Kuwait-based distributor and is expected to be available in local markets by July 2025.

This strategic expansion builds upon Dream Water's existing success with sleep gummies in Canadian and U.S. markets, complementing their current liquid shot offerings in the Middle East. The move represents a calculated effort to grow the brand's presence through partnerships with local distributors who possess regional market expertise.

Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced the launch of Dream Water® 6-Count Sleep Gummies in the Canadian market. This new product follows the successful introduction of their 60-count Dream Water® Gummies in February 2024.

The 6-Count Sleep Gummies will be available to distributors, retailers, and e-commerce channels in March 2025. According to CEO Gord Davey, this strategic launch aims to capture growth opportunities in the travel and convenience retail channels while strengthening the company's position in sleep solutions.

The product will be distributed nationwide through Delivra Health's established retail and e-commerce partners, building on the momentum of Dream Water Sleep Gummies in both Canadian and US markets.

Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) reported its Q2 2025 financial results, showcasing a 34% net revenue growth to $2,754, up $704 from the same quarter last year. The growth was primarily driven by higher sales of Dream Water® in the U.S. and Canada.

Key financial metrics include:

• Gross profit of $1,294 with a 47% margin (down from 54% last year)
• Increased SG&A expenses of $1,544, up 22% year-over-year
• Adjusted EBITDA of $(194) compared to $(84) in the same period last year

The company increased marketing investments and consumer promotional programs across all channels. Six-month results showed total net revenue of $5,917, a 3% increase, while gross profit decreased to $2,891 with a 49% margin. Management remains confident in achieving their commercial and financial objectives for the fiscal year.

Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced it will release its financial results for Q2 fiscal 2025, covering the three and six months ended December 31, 2024. The company will host a conference call on Thursday, February 27, 2025, at 11:00 a.m. EST to discuss these results.

The conference call will feature a Q&A session led by President and CEO Gord Davey and CFO Jack Tasse. Interested parties can join via toll-free number 1-833-752-2525 (Canada/USA) or +1-647-846-2674 (International). Participants are advised to dial in 10 minutes before the scheduled start time. A replay will be available on the company's investor page following the call.

Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced a share consolidation effective February 21, 2025. The consolidation will be implemented on a 1-for-10 basis, reducing the outstanding common shares from 312,617,854 to approximately 31,261,785.

The company's name will remain unchanged, with new CUSIP number 24703H201 and ISIN number CA24703H2019. The consolidation will adjust the exercise price and number of shares for existing stock options and warrants accordingly.

Registered shareholders holding physical certificates will receive a letter of transmittal to exchange their certificates, while beneficial shareholders holding shares through brokers won't need to complete this process.

Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has announced plans to implement a 10:1 share consolidation, which will reduce the company's outstanding common shares from 312,617,854 to approximately 31,261,785. The consolidation, approved by the board on January 27, 2025, aims to enhance market appeal and facilitate organic growth.

Shareholders' ownership percentages and voting power will remain largely unchanged, with only minor adjustments for fractional shares. The consolidation will also proportionally adjust the exercise prices and number of shares for existing stock options and warrants. The implementation remains subject to TSX Venture Exchange approval, with the effective date to be announced later.

Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) reported financial results for Q1 fiscal 2025. Net revenue decreased 14% to $3,163,000 from $3,671,000 in the same period last year, primarily due to reduced Dream Water sales. Gross profit margin slightly declined to 51% from 52%. The company maintained positive Adjusted EBITDA of $16,000, down from $683,000 last year. Expenses increased 20% to $1,607,000, driven by higher investments in sales and marketing campaigns. The company reported a net loss of $478,000 compared to a profit of $226,000 in the previous year.

Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) reported positive financial results for fiscal 2024, ending June 30, 2024. The company, positioned in the health and wellness sector, saw a 26% year-over-year net revenue growth to $12,378, driven by increased sales in the USA and Canada. Gross profit margin improved to 52% from 49% in the previous year. Adjusted EBITDA increased by 68% to $871K compared to fiscal 2023. The company's portfolio, featuring Dream Water® and LivRelief™ brands, focuses on relief from sleeplessness, chronic pain, and anxiety. CEO Gord Davey emphasized the company's consistent improvement over the past four years and anticipated continued revenue and profitability growth for fiscal 2025.